User profiles for Boaz Palterer

Boaz Palterer

Boston Children's Hospital | Harvard Medical School
Verified email at childrens.harvard.edu
Cited by 751

[HTML][HTML] Bench to bedside review of myositis autoantibodies

B Palterer, G Vitiello, A Carraresi, MG Giudizi… - Clinical and Molecular …, 2018 - Springer
Idiopathic inflammatory myopathies represent a heterogeneous group of autoimmune diseases
with systemic involvement. Even though numerous specific autoantibodies have been …

Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis

…, D Giavarina, F Franceschini, M Infantino, B Palterer… - RMD open, 2023 - rmdopen.bmj.com
Objective The first biomarker associated with the rheumatoid arthritis is rheumatoid factor (RF)
and since the earliest reports a role has been proposed in the diagnosis and in the …

[HTML][HTML] NADPH oxidase deficiency: a multisystem approach

…, O Delmonte, M Migliavacca, B Palterer… - … medicine and cellular …, 2017 - hindawi.com
The immune system is a complex system able to recognize a wide variety of host agents,
through different biological processes. For example, controlled changes in the redox state are …

SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation

…, D Fink, S Majumdar, B Palterer… - Blood, The Journal …, 2021 - ashpublications.org
Sterile alpha motif (SAM) and Src homology-3 (SH3) domain-containing 3 (SASH3), also
called SH3-containing lymphocyte protein (SLY1), is a putative adaptor protein that is …

The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants

…, T Khan, A Gervais, R Krüger, M Völler, B Palterer… - Science, 2024 - science.org
We describe humans with rare biallelic loss-of-function PTCRA variants impairing pre–α T
cell receptor (pre-TCRα) expression. Low circulating naive αβ T cell counts at birth persisted …

Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis

…, M Sciumè, R Parente, M Triggiani, B Palterer… - Journal of Allergy and …, 2023 - Elsevier
Background Systemic mastocytosis (SM) encompasses a heterogeneous group of clonal
disorders characterized by abnormal expansion of mast cells (MCs). Beyond KIT and other …

Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRI

…, A Vultaggio, A Mazzoni, B Palterer… - European journal of …, 2018 - Wiley Online Library
Even if omalizumab is broadly used in the treatment of severe, allergic asthma, the
immunological effects in long‐term treated patients have not been fully elucidated. To this aim, a …

[HTML][HTML] An Italian multicenter study on anti-NXP2 antibodies: clinical and serological associations

…, P Migliorini, C Montecucco, B Palterer… - Clinical Reviews in …, 2022 - Springer
The identification of anti-NXP2 antibodies is considered a serological marker of dermatomyositis
(DM), with calcinosis, severe myositis and, in some reports, with cancer. Historically, …

[HTML][HTML] Anti-U11/U12 antibodies as a rare but important biomarker in patients with systemic sclerosis: a narrative review

MJ Fritzler, C Bentow, L Beretta, B Palterer… - Diagnostics, 2023 - mdpi.com
Anti-nuclear (ANA) are present in approximately 90% of systemic sclerosis (SSc) patients
and are key biomarkers in supporting the diagnosis and determining the prognosis of this …

Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine: Anti-PAD4 …

L Martinez-Prat, B Palterer, G Vitiello… - Expert review of …, 2019 - Taylor & Francis
Introduction: The protein-arginine deiminase (PAD) 4 enzyme plays an important role in the
pathogenesis of rheumatoid arthritis (RA) and also represents an antigenic target. Anti-PAD4 …